Travere Therapeutics (TVTX) Net Income towards Common Stockholders Growth (5y) (2018 - 2026)
Travere Therapeutics (TVTX) Net Income towards Common Stockholders Growth (5y) (2018 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Travere Therapeutics |
5.07 Bn |
4.99 Bn |
102.38 Mn |
| Date | Value |
|---|
| Mar 31, 2026 |
60.78% |
| Dec 31, 2025 |
17.11% |
| Dec 31, 2024 |
14.87% |
| Sep 30, 2024 |
72.35% |
| Jun 30, 2024 |
54.47% |
| Mar 31, 2024 |
69.80% |
| Dec 31, 2023 |
26.70% |
| Sep 30, 2023 |
44.96% |
| Jun 30, 2023 |
22.25% |
| Mar 31, 2023 |
20.65% |
| Dec 31, 2022 |
25.59% |
| Sep 30, 2022 |
22.95% |
| Jun 30, 2022 |
24.42% |
| Mar 31, 2022 |
20.31% |
| Dec 31, 2021 |
-59.49% |
| Sep 30, 2021 |
0.81% |
| Jun 30, 2021 |
-23.82% |
| Mar 31, 2021 |
-46.73% |
| Dec 31, 2020 |
-118.02% |
| Sep 30, 2020 |
-17.22% |
